Surgical Treatment of Proximal Femoral Fractures Under Peripheral Regional Anesthesia. A Prospective Pilot Study
Overview
- Phase
- N/A
- Intervention
- Ropivacaine (sciatic nerve block)
- Conditions
- Hip Fractures
- Sponsor
- Helios Research Center
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Success Rate (Conversion to General Anesthesia)
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The study investigates whether treatment of proximal femoral fractures is possible using a peripheral regional anesthesia technique.
Detailed Description
The study investigates whether treatment of proximal femoral fractures is possible using a peripheral regional anesthesia technique. After positioning on the non-fractured side, a double injection technique is used (dual guidance concept: nerve stimulation and sonography). The injections are performed parasacrally (blockade of the sacral plexus under the piriformis muscle) and lumbar paravertebrally (psoas compartment block and transmuscular quadratus lumborum block). Per block 20 ml ropivacaine 0.375% is administered (total dose: 225mg ropivacaine). The study examines the success rate (rate of successfully performed nerve blockade; need for supplemental medication: sufentanil and/or propofol; conversion rate to general anesthesia), circulatory stability (need for application of ephedrine or norepinephrine) and side effects.
Investigators
Dr.med.Ronald Seidel
Principal Investigator
Helios Research Center
Eligibility Criteria
Inclusion Criteria
- •proximal femoral fracture
- •older then 18 years
- •written informed consent
Exclusion Criteria
- •local or systematic inflammation
- •allergy to ropivacaine
- •participate in other studies
- •body mass index over 35
- •periprosthetic fractures
Arms & Interventions
intertrochanteric femoral fractures
geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
Intervention: Ropivacaine (sciatic nerve block)
intertrochanteric femoral fractures
geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
Intervention: Ropivacaine (lumbar plexus block L2-L4)
intertrochanteric femoral fractures
geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
Intervention: Ropivacaine (lumbar plexus block Th12-L1)
neck femur fractures
geriatric patients with neck of femur fracture who have consented to the study intervention
Intervention: Ropivacaine (sciatic nerve block)
neck femur fractures
geriatric patients with neck of femur fracture who have consented to the study intervention
Intervention: Ropivacaine (lumbar plexus block L2-L4)
neck femur fractures
geriatric patients with neck of femur fracture who have consented to the study intervention
Intervention: Ropivacaine (lumbar plexus block Th12-L1)
subtrochanteric femoral fractures
geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
Intervention: Ropivacaine (sciatic nerve block)
subtrochanteric femoral fractures
geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
Intervention: Ropivacaine (lumbar plexus block L2-L4)
subtrochanteric femoral fractures
geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
Intervention: Ropivacaine (lumbar plexus block Th12-L1)
Outcomes
Primary Outcomes
Success Rate (Conversion to General Anesthesia)
Time Frame: during surgery
number of participants with need for conversion to general anesthesia
Success Rate (Supplemental Medication)
Time Frame: during surgery
number of participants with need for supplemental analgesic medication (sufentanil)
Secondary Outcomes
- Circulation Stability(during surgery)